Effects of a new calcium antagonist, mibefradil (Ro 40-5967), on silent ischemia in patients with stable chronic angina pectoris: A multicenter placebo-controlled study

被引:90
作者
Braun, S
vanderWall, EE
Emanuelsson, H
Kobrin, I
机构
[1] LEIDEN UNIV HOSP,LEIDEN,NETHERLANDS
[2] SAHLGRENS UNIV HOSP,GOTHENBURG,SWEDEN
[3] HOFFMANN LA ROCHE AG,BASEL,SWITZERLAND
关键词
D O I
10.1016/0735-1097(95)00472-6
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives. The purpose of this study was to evaluate the effects of mibefradil (Ro 40-5967) on the frequency and duration of episodes of asymptomatic ischemia in patients with stable angina pectoris and to determine the most efficient single therapeutic dose of this drug. Background. Mibefradil is a novel calcium channel antagonist that shows a high bioavailability, induces no reflex tachycardia and has no negative inotropic effects. Methods. In a multicenter, double-blind, placebo-controlled, parallel design trial, 126 patients with chronic stable angina pectoris were studied. After 1 week of a placebo run-in period, patients were randomized to receive 25, 50, 100, 150 mg of mibefradil or placebo for 2 weeks, Ambulatory 48-h electrocardiographic (EGG) monitoring was performed at the end of both the placebo run in period and the active treatment period. Results. Compared with placebo, mibefradil was associated with significantly less ischemia as manifested during ambulatory ECG monitoring. In the 150- and 100-mg groups, respectively, the drug resulted in a 73% and 63% reduction in the frequency of episodes of ST segment depression and a 78% and 58% reduction in the total duration of ST segment depression. Highly significant linear dose-response relations were present across all treatment groups for ischemic episodes and ischemia duration (p < 0.001). Electrocardiographic abnormalities related to treatment were first-degree atrioventricular block, sinus bradycardia and short Wenckebach episodes, observed during sleep on Holter monitoring. All ECG events were dose related. Conclusions. Mibefradil is a new, safe, well tolerated and very effective dose-dependent anti-ischemic calcium channel antagonist.
引用
收藏
页码:317 / 322
页数:6
相关论文
共 34 条
  • [1] BAKX LM, 1995, AM HEART J, V130, P748
  • [2] CA2+ CHANNEL ACTIONS OF THE NONDIHYDROPYRIDINE CA2+ CHANNEL ANTAGONIST RO-40-5967 IN VASCULAR MUSCLE-CELLS CULTURED FROM DOG CORONARY AND SAPHENOUS ARTERIES
    BIAN, K
    HERMSMEYER, K
    [J]. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1993, 348 (02) : 191 - 196
  • [3] CORONARY VASOSPASM - OBSERVATIONS LINKING THE CLINICAL SPECTRUM OF ISCHEMIC-HEART-DISEASE TO THE DYNAMIC PATHOLOGY OF CORONARY ATHEROSCLEROSIS
    BROWN, BG
    [J]. ARCHIVES OF INTERNAL MEDICINE, 1981, 141 (06) : 716 - 722
  • [4] REFLEX CONSTRICTION OF SIGNIFICANT CORONARY STENOSIS AS A MECHANISM CONTRIBUTING TO ISCHEMIC LEFT-VENTRICULAR DYSFUNCTION DURING ISOMETRIC-EXERCISE
    BROWN, BG
    LEE, AB
    BOLSON, EL
    DODGE, HT
    [J]. CIRCULATION, 1984, 70 (01) : 18 - 24
  • [5] DYNAMIC MECHANISMS IN HUMAN CORONARY STENOSIS
    BROWN, BG
    BOLSON, EL
    DODGE, HT
    [J]. CIRCULATION, 1984, 70 (06) : 917 - 922
  • [6] MULTIPLE TEST PROCEDURES IN CLINICAL DOSE FINDING STUDIES
    BUDDE, M
    BAUER, P
    [J]. JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1989, 84 (407) : 792 - 796
  • [7] FEATURES OF THE EXERCISE TEST THAT REFLECT THE ACTIVITY OF ISCHEMIC-HEART-DISEASE OUT OF HOSPITAL
    CAMPBELL, S
    BARRY, J
    ROCCO, MB
    NABEL, EG
    MEADWALTERS, K
    REBECCA, GS
    SELWYN, AP
    [J]. CIRCULATION, 1986, 74 (01) : 72 - 80
  • [8] THE STRUCTURALLY NOVEL CA-2+ CHANNEL BLOCKER RO 40-5967, WHICH BINDS TO THE [H-3] DESMETHOXYVERAPAMIL RECEPTOR, IS DEVOID OF THE NEGATIVE INOTROPIC EFFECTS OF VERAPAMIL IN NORMAL AND FAILING RAT HEARTS
    CLOZEL, JP
    VENIANT, M
    OSTERRIEDER, W
    [J]. CARDIOVASCULAR DRUGS AND THERAPY, 1990, 4 (03) : 731 - 736
  • [9] EFFECTS OF RO-40-5967, A NOVEL CALCIUM-ANTAGONIST, ON MYOCARDIAL-FUNCTION DURING ISCHEMIA INDUCED BY LOWERING CORONARY PERFUSION-PRESSURE IN DOGS - COMPARISON WITH VERAPAMIL
    CLOZEL, JP
    BANKEN, L
    OSTERRIEDER, W
    [J]. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1989, 14 (05) : 713 - 721
  • [10] RO 40-5967 - A NEW NONDIHYDROPYRIDINE CALCIUM-ANTAGONIST
    CLOZEL, JP
    OSTERRIEDER, W
    KLEINBLOESEM, CH
    WELKER, HA
    SCHLAPPI, B
    TUDOR, R
    HEFTI, F
    SCHMITT, R
    EGGERS, H
    [J]. CARDIOVASCULAR DRUG REVIEWS, 1991, 9 (01): : 4 - 17